ASCO: Continuing avastin with 2nd-line chemo ups survival
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...
Jun 5, 2012
0
0